Stay updated on CIN-107 in Primary Aldosteronism Clinical Trial
Sign up to get notified when there's something new on the CIN-107 in Primary Aldosteronism Clinical Trial page.

Latest updates to the CIN-107 in Primary Aldosteronism Clinical Trial page
- Check3 days agoChange DetectedAdded Revision: v3.5.2; removed Revision: v3.5.0.SummaryDifference0.1%

- Check11 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check32 days agoChange DetectedRevision: v3.5.0 added; Revision: v3.4.3 removed.SummaryDifference0.1%

- Check40 days agoChange DetectedPage revision updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check47 days agoChange DetectedResults were posted for CIN-107 in adults with primary aldosteronism, including treatment-emergent adverse events, 12-week SBP/DBP changes, BP response rates, and pharmacodynamic marker responses (Part 1). Previously listed safety and efficacy data elements were removed from the page.SummaryDifference3%

- Check68 days agoChange DetectedAdded Revision: v3.4.2; removed the funding/operating-status notice and the previous Revision: v3.4.1.SummaryDifference0.4%

- Check75 days agoChange DetectedAdded a government funding notice about potential delays and status updates, and updated the page revision from v3.4.0 to v3.4.1.SummaryDifference0.4%

Stay in the know with updates to CIN-107 in Primary Aldosteronism Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CIN-107 in Primary Aldosteronism Clinical Trial page.